Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon, Integrated DNA Technologies Ink Locked Nucleic Acid Licensing Deal

NEW YORK, Jan. 5 (GenomeWeb News) - Denmark's Exiqon has licensed certain rights to its locked nucleic acid technology to Integrated DNA Technologies (IDT), the companies said today.

 

Under the terms of the deal, IDT has non-exclusive rights to manufacture and sell locked nucleic acid oligonucleotides for the genomics research market and will receive access to certain Exiqon know-how related to the technology.

 

Financial terms of the arrangement were not disclosed.

 

According to the companies, a locked nucleic acid is a proprietary nucleic acid analog that is easily incorporated into synthetic DNA oligos. Locked nucleic acid probes, they added, have successfully been used in both RT-PCR-based expression profiling and SNP genotyping assays, as well as in expression microarrays and siRNA oligos for target validation.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.